Comparative Pharmacology
Head-to-head clinical analysis: MINOXIDIL FOR MEN versus TRANSDERM NITRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOXIDIL FOR MEN versus TRANSDERM NITRO.
MINOXIDIL (FOR MEN) vs TRANSDERM-NITRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a direct-acting peripheral vasodilator that opens ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation. In hair follicles, it promotes hair growth by increasing blood flow, stimulating prostaglandin synthesis, and prolonging the anagen phase.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Oral: 2.5-5 mg once daily; may increase to 10 mg once daily if needed. Topical: 5% solution, 1 mL applied to dry scalp twice daily; 5% foam, half a capful applied twice daily; 2% solution, 1 mL applied twice daily.
Initial dose 0.2-0.4 mg/hour transdermally once daily. Titrate to 0.4-0.8 mg/hour. Maximum 0.8 mg/hour.
None Documented
None Documented
Terminal half-life: 3.5-4.5 hours. Clinical context: Short half-life necessitates twice-daily dosing for hypertension; for topical use, systemic absorption is minimal so half-life less relevant.
Terminal elimination half-life is approximately 1-4 minutes after IV administration due to rapid metabolism. After transdermal application, the apparent half-life is 3-4 hours due to continued absorption from the skin depot, resulting in a prolonged clinical effect.
Renal: 85-90% (primarily unchanged drug and metabolites). Biliary/fecal: <5%.
Renal (primarily) and biliary; ~60-80% of the dose is excreted renally as metabolites, with <1% unchanged. Fecal excretion accounts for ~10-20%.
Category A/B
Category C
Vasodilator / Hair Growth Stimulant
Vasodilator